

References

S-97

1. Guidelines for Surgery and Procedures Performed in the Inpatient Setting. Change Healthcare LLC. 2018
2. Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. *J Urol*. 2018;200(3):612-619.
3. Parsons JK, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic Hyperplasia: AUA guideline. 2020.
4. Sundaram D, Sankaran PK, Raghunath G, et al. Correlation of prostate gland size and uroflowmetry in patients with lower urinary tract symptoms. *J Clin Diagn Res*. 2017;11(5):AC01-AC04.
5. Jones P, Rajkumar GN, Rai BP, et al. Medium-term outcomes of urolift (minimum 12 months follow-up): Evidence from a systematic review. *Urology*. 2016;97:20-24.
6. Bozkurt A, Karabakan M, Keskin E, et al. Prostatic urethral lift: A new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Int*. 2016;96(2):202-6.
7. Ray A, Morgan H, Wilkes A, Carter K, Carolan-Rees G. The urolift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A NICE medical technology guidance. *Appl Health Econ Health Policy*. 2016;14(5):515-26.
8. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *Int Urol Nephrol*. 2020;52(6):999-1008.
9. Sievert KD, Schonhaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: A multicenter German evaluation after 2 years. *World J Urol*. 2019;37(7):1353-1360.
10. Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P. Prostatic urethral lift for the treatment of lower urinary tract symptoms in

men with benign prostatic hyperplasia. *Cochrane Database Syst Rev.* 2019;25;5(5):CD012832.

11. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int.* 2017;119(5):767-775.
12. Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical reintervention rate after prostatic urethral lift: Systematic review and meta-analysis involving over 2,000 patients. *J Urol.* 2020;204(5):1019-1026.
13. Roehrborn CG. Prostatic urethral lift: A unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Clin North Am.* 2016;43(3):357-69.
14. Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol.* 2017;24(3):8802-8813.
15. Rukstalis D, Grier D, Stroup SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. *Prostate Cancer Prostatic Dis.* 2019 Sep;22(3):411-419.
16. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P. Prostatic urethral lift: Does size matter? *J Endouro* 2018;32(7):635-638.
17. Eure G, Gange S, Walter P, et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. *J Endourol.* 2019;33(7):576-584.
18. National Comprehensive Cancer Network. Prostate Cancer. Version 3.2020. Accessed December 30, 2020.
19. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7-30.
20. Gao L, Yang L, Qian S, et al. Cryosurgery would be an effective option for clinically localized prostate cancer: A Meta-analysis and systematic review. *Sci Rep.* 2016;6:27490.

21. Tay KJ, Polascik TJ, Elshafei A, et al. Primary cryotherapy for high-grade clinically localized prostate cancer: Oncologic and functional outcomes from the COLD registry. *J Endourol*. 2016;30(1):43-8.
22. Siddiqui KM, Billia M, Al-Zahrani A, et al. Long-term oncologic outcomes of salvage cryoablation for radio-recurrent prostate cancer. *J Urol*. 2016;196(4):1105-11.
23. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. [NG131]. 2019. Accessed December 31, 2020.
24. Natarajan S, Raman S, Priester AM, et al. Focal laser ablation of prostate cancer: Phase I clinical trial. *J Urol*. 2016 Jul;196(1):68-75.
25. Lian H, Zhuang J, Yang R, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. *Int Urol Nephrol*. 2016;48(1):85-90.
26. Westwood J, Geraghty R, Jones P, et al. Rezūm: A new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol*. 2018;10(11):327-333.
27. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezūm system study: Convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. 2018;111:1-9.
28. Kang TW, Jung JH, Hwang EC, et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2020;25;3(3):CD013251.
29. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology*. 2019;126:171-179.
30. Hayes, Inc. Hayes Health Technology Assessment. *Prostatic urethral lift (UroLift System) for treatment of symptoms associated with benign prostatic hyperplasia*. Lansdale, PA: Hayes, Inc.; 06/09/2020.
31. Hayes, Inc. Comparative Effectiveness Review. *Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer*. Lansdale, PA: Hayes, Inc.; 07/27/2017.

32. Hayes, Inc. Health Technology Assessment. *High-intensity focused ultrasound for salvage therapy of recurrent prostate cancer*. Lansdale, PA: Hayes, Inc.; 03/30/2017.